MT101-5 / Mthera Pharma - LARVOL DELTA

De novo identification of potent ingredients for proteasome activation in MT101-5 using an AI-driven approach. (PubMed, Biomed Pharmacother) - "Two diterpenoids mitigated behavioural deficits and dopaminergic neuron loss in mice subjected to subacute MPTP administration (30 mg/kg/day for 5 days). These results provide preliminary evidence supporting the therapeutic potential of the active ingredients in MT101-5 for the prevention or treatment of PD."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Targeted Protein Degradation • NR4A2

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Mthera Pharma Co., Ltd. | Trial primary completion date: Dec 2024 ➔ Jul 2025

Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Mthera Pharma Co., Ltd. | Initiation date: Jan 2024 ➔ Jul 2024

Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Mthera Pharma Co., Ltd.

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease